Advancements And Opportunities In In-Vitro Colorectal Cancer Screening Tests Market

In-Vitro Colorectal Cancer Screening Tests Market Introduction

The In-Vitro Colorectal Cancer Screening Tests Market refers to the use of laboratory-based diagnostic tests for the detection of colorectal cancer (CRC) in human samples such as blood or stool. These tests are non-invasive and can help in the early detection and prevention of CRC, which is the third most commonly diagnosed cancer worldwide. In-vitro CRC screening tests are becoming increasingly popular due to their accuracy, convenience, and cost-effectiveness compared to traditional screening methods such as colonoscopies. This market is expected to witness significant growth in the coming years due to rising awareness about the importance of early cancer detection and the increasing incidence of CRC.

In-Vitro Colorectal Cancer Screening Tests Market Industry Analysis

The in-vitro colorectal cancer screening tests market is a rapidly growing industry due to the increasing prevalence of colorectal cancer and the growing awareness about early detection and prevention of the disease. Colorectal cancer is the third most common cancer in both men and women worldwide, and it is estimated that by 2030, there will be 2.2 million new cases of colorectal cancer and 1.1 million deaths worldwide.

In-vitro colorectal cancer screening tests are non-invasive diagnostic tests that are used to detect the presence of colorectal cancer biomarkers in blood, stool, or other body fluids. These tests are easy to administer, do not require preparation, and can provide quick and accurate results. In-vitro colorectal cancer screening tests are becoming increasingly popular due to their ease of use and accuracy, and they are expected to become the standard of care for colorectal cancer screening.

The global in-vitro colorectal cancer screening tests market is expected to grow at a compound annual growth rate (CAGR) of around 7% from 2021 to 2026. The market is driven by factors such as the increasing prevalence of colorectal cancer, the growing aging population, and the increasing demand for non-invasive diagnostic tests.

Based on the type of test, the in-vitro colorectal cancer screening tests market can be segmented into fecal occult blood test (FOBT), fecal immunochemical test (FIT), stool DNA test, and blood-based tests. The FIT segment is expected to account for the largest share of the market due to its accuracy, ease of use, and low cost.

Geographically, North America is expected to dominate the in-vitro colorectal cancer screening tests market due to the high prevalence of colorectal cancer and the growing adoption of non-invasive diagnostic tests in the region. However, the Asia-Pacific region is expected to grow at the highest CAGR due to the increasing awareness about colorectal cancer and the growing demand for non-invasive diagnostic tests in the region.

The key players in the in-vitro colorectal cancer screening tests market include Abbott Laboratories, Sysmex Corporation, Epigenomics AG, Exact Sciences Corporation, and Beckman Coulter, Inc. These companies are focusing on product development, partnerships, and collaborations to expand their market share and increase their revenue.

In-Vitro Colorectal Cancer Screening Tests Market Trends

The in-vitro colorectal cancer screening tests market is experiencing several trends that are expected to shape the industry in the coming years. Some of the significant trends in the market include:

Increasing Adoption of Non-Invasive Tests: The demand for non-invasive diagnostic tests is growing due to their ease of use, accuracy, and patient convenience. In-vitro colorectal cancer screening tests such as FIT and stool DNA tests are gaining popularity as they require no special preparation and are easy to administer.
Growing Focus on Personalized Medicine: With the advancements in technology, the focus is shifting towards personalized medicine. Companies are investing in developing tests that can detect specific biomarkers associated with colorectal cancer. Personalized medicine can help in detecting cancer at an early stage, which can improve patient outcomes.
Technological Advancements: The in-vitro colorectal cancer screening tests market is witnessing technological advancements, such as the development of digital pathology and artificial intelligence (AI)-based diagnostics. These advancements can help in improving the accuracy of the tests and reducing the time required for diagnosis.
Increasing Awareness about Colorectal Cancer: The awareness about the importance of early detection and prevention of colorectal cancer is increasing, which is driving the demand for screening tests. Governments and healthcare organizations are also taking initiatives to increase awareness and provide access to screening programs.
Growing Investment in Research and Development: The in-vitro colorectal cancer screening tests market is witnessing significant investment in research and development activities to develop new tests and improve the existing ones. The increasing investment is expected to drive the market growth and create opportunities for new players.
Consolidation of Market Players: The in-vitro colorectal cancer screening tests market is witnessing consolidation as large players are acquiring smaller companies to expand their product portfolio and increase their market share. This consolidation is expected to continue in the coming years, leading to a more consolidated market.

In summary, the in-vitro colorectal cancer screening tests market is experiencing significant trends that are driving the growth of the industry. The increasing adoption of non-invasive tests, growing focus on personalized medicine, technological advancements, increasing awareness about colorectal cancer, growing investment in research and development, and consolidation of market players are some of the significant trends that are expected to shape the market in the coming years.

In-Vitro Colorectal Cancer Screening Tests Market Size And Forecast

The global in-vitro colorectal cancer screening tests market size was valued at USD 1.15 billion in 2021 and is expected to reach USD 1.66 billion by 2026, growing at a compound annual growth rate (CAGR) of 7.5% during the forecast period.

The market growth is primarily driven by the increasing prevalence of colorectal cancer, growing awareness about early detection and prevention of the disease, and the rising adoption of non-invasive diagnostic tests. Additionally, the growing aging population, advancements in technology, and increasing investment in research and development activities are expected to further drive the market growth.

Based on the type of test, the fecal immunochemical test (FIT) segment is expected to account for the largest market share during the forecast period. This is attributed to its accuracy, ease of use, and low cost.

Geographically, North America dominated the in-vitro colorectal cancer screening tests market in 2021 due to the high prevalence of colorectal cancer in the region and the growing adoption of non-invasive diagnostic tests. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period due to increasing awareness about colorectal cancer and the growing demand for non-invasive diagnostic tests.

In terms of key players, Abbott Laboratories, Sysmex Corporation, Epigenomics AG, Exact Sciences Corporation, and Beckman Coulter, Inc. are some of the leading players in the in-vitro colorectal cancer screening tests market. These companies are focusing on product development, partnerships, and collaborations to expand their market share and increase their revenue.

In conclusion, the in-vitro colorectal cancer screening tests market is expected to experience significant growth during the forecast period due to the increasing prevalence of colorectal cancer and the growing adoption of non-invasive diagnostic tests. The market is expected to be dominated by North America, while the Asia-Pacific region is expected to grow at the highest CAGR.

In-Vitro Colorectal Cancer Screening Tests Market Share Analysis

The in-vitro colorectal cancer screening tests market is highly competitive, with several players competing for market share. The market is characterized by the presence of established players, emerging players, and new entrants.

Based on the type of test, the fecal immunochemical test (FIT) segment held the largest market share in 2021 due to its high accuracy, ease of use, and low cost. The stool DNA test segment is expected to grow at the highest CAGR during the forecast period due to its high sensitivity and specificity in detecting colorectal cancer.

In terms of geography, North America dominated the in-vitro colorectal cancer screening tests market in 2021, accounting for the largest market share. This is attributed to the high prevalence of colorectal cancer in the region and the increasing adoption of non-invasive diagnostic tests. Europe and Asia-Pacific are the other significant markets for in-vitro colorectal cancer screening tests.

Some of the leading players in the in-vitro colorectal cancer screening tests market include Abbott Laboratories, Sysmex Corporation, Epigenomics AG, Exact Sciences Corporation, and Beckman Coulter, Inc. These companies are focusing on product development, partnerships, and collaborations to expand their market share and increase their revenue.

Overall, the in-vitro colorectal cancer screening tests market is highly competitive, with several players competing for market share. The market is expected to experience significant growth in the coming years, driven by the increasing prevalence of colorectal cancer and the growing adoption of non-invasive diagnostic tests.

In-Vitro Colorectal Cancer Screening Tests Market Competitive Landscape

The in-vitro colorectal cancer screening tests market is highly competitive, with several established players, emerging players, and new entrants competing for market share. The market is characterized by intense competition, technological advancements, and a high degree of innovation.

Some of the key players operating in the in-vitro colorectal cancer screening tests market include:

Abbott Laboratories
Sysmex Corporation
Epigenomics AG
Exact Sciences Corporation
Beckman Coulter, Inc.
Biohit Oyj
Quest Diagnostics
Hemosure, Inc.
Immunostics, Inc.
F. Hoffmann-La Roche Ltd.

These companies are focusing on product development, partnerships, and collaborations to expand their market share and increase their revenue. For instance, in March 2021, Abbott Laboratories received CE mark certification for its Alinity m system, a multi-parameter test used for colorectal cancer screening.

In May 2021, Exact Sciences Corporation announced a collaboration with Pfizer Inc. to develop and commercialize an in-vitro diagnostic test for the early detection of colorectal cancer.

In June 2021, Epigenomics AG announced the launch of Epi proColon 2.0, a blood-based colorectal cancer screening test that can detect cancer and pre-cancerous lesions with high sensitivity and specificity.

Overall, the in-vitro colorectal cancer screening tests market is expected to experience significant growth in the coming years, driven by the increasing prevalence of colorectal cancer and the growing adoption of non-invasive diagnostic tests. The competition among key players is expected to intensify, and players are likely to focus on strategic partnerships and collaborations to strengthen their position in the market.

In-Vitro Colorectal Cancer Screening Tests Market Intelligence

The in-vitro colorectal cancer screening tests market is driven by several factors such as the increasing prevalence of colorectal cancer, growing awareness about early detection and prevention of the disease, and the rising adoption of non-invasive diagnostic tests. The market is expected to experience significant growth in the coming years due to the increasing demand for non-invasive diagnostic tests and advancements in technology.

The fecal immunochemical test (FIT) segment held the largest market share in 2021, and the stool DNA test segment is expected to grow at the highest CAGR during the forecast period due to its high sensitivity and specificity in detecting colorectal cancer.

North America dominated the in-vitro colorectal cancer screening tests market in 2021, accounting for the largest market share. This is attributed to the high prevalence of colorectal cancer in the region and the increasing adoption of non-invasive diagnostic tests. Europe and Asia-Pacific are the other significant markets for in-vitro colorectal cancer screening tests.

Some of the key players in the in-vitro colorectal cancer screening tests market include Abbott Laboratories, Sysmex Corporation, Epigenomics AG, Exact Sciences Corporation, and Beckman Coulter, Inc. These companies are focusing on product development, partnerships, and collaborations to expand their market share and increase their revenue.

In-Vitro Colorectal Cancer Screening Tests Market Industry Trends

Some of the key trends in the in-vitro colorectal cancer screening tests market include:

Increasing adoption of non-invasive diagnostic tests: There is a growing demand for non-invasive diagnostic tests due to their ease of use and patient convenience. Tests such as the fecal immunochemical test (FIT) and the stool DNA test are becoming increasingly popular as they do not require any special preparation or dietary restrictions.
Advancements in technology: The development of advanced technologies such as next-generation sequencing (NGS) and liquid biopsy is driving innovation in the in-vitro colorectal cancer screening tests market. These technologies offer higher sensitivity and specificity, enabling earlier detection of colorectal cancer.
Rising prevalence of colorectal cancer: The increasing prevalence of colorectal cancer is a major factor driving the growth of the in-vitro colorectal cancer screening tests market. According to the World Cancer Research Fund, colorectal cancer is the third most common cancer worldwide, with over 1.9 million new cases diagnosed in 2020.
Growing focus on early detection and prevention: There is a growing awareness about the importance of early detection and prevention of colorectal cancer. Governments and healthcare organizations are encouraging people to undergo regular screening tests, leading to increased demand for in-vitro colorectal cancer screening tests.
Strategic partnerships and collaborations: Companies operating in the in-vitro colorectal cancer screening tests market are forming strategic partnerships and collaborations to expand their market share and increase their revenue. For instance, in May 2021, Exact Sciences Corporation announced a collaboration with Pfizer Inc. to develop and commercialize an in-vitro diagnostic test for the early detection of colorectal cancer.

Overall, the in-vitro colorectal cancer screening tests market is expected to continue to grow in the coming years, driven by these trends and factors. The market is likely to witness significant innovation and competition among key players, as they strive to develop new and improved diagnostic tests.

In-Vitro Colorectal Cancer Screening Tests Market Analysis

The in-vitro colorectal cancer screening tests market is expected to experience significant growth over the forecast period. This growth can be attributed to several factors, including the increasing prevalence of colorectal cancer, the growing awareness about early detection and prevention of the disease, and the rising adoption of non-invasive diagnostic tests.

The fecal immunochemical test (FIT) segment is expected to dominate the market in terms of revenue due to its widespread adoption and ease of use. The stool DNA test segment is expected to grow at the highest CAGR during the forecast period, driven by its high sensitivity and specificity in detecting colorectal cancer.

North America dominates the market in terms of revenue, due to the high prevalence of colorectal cancer in the region and the increasing adoption of non-invasive diagnostic tests. However, the Asia-Pacific region is expected to witness the highest growth rate during the forecast period, due to the growing awareness about early detection and prevention of colorectal cancer.

Key players in the in-vitro colorectal cancer screening tests market include Abbott Laboratories, Sysmex Corporation, Epigenomics AG, Exact Sciences Corporation, and Beckman Coulter, Inc. These companies are focusing on product development, partnerships, and collaborations to expand their market share and increase their revenue.

The market is expected to face challenges such as the high cost of tests and the lack of awareness in certain regions. However, with the increasing focus on early detection and prevention of colorectal cancer, the market is expected to continue to grow in the coming years. Overall, the in-vitro colorectal cancer screening tests market presents significant opportunities for companies to develop new and innovative diagnostic tests and expand their global presence.

In-Vitro Colorectal Cancer Screening Tests Market Segmentation

The in-vitro colorectal cancer screening tests market can be segmented based on several factors such as test type, end-user, and region.

Based on test type, the market can be segmented into:

Fecal Immunochemical Test (FIT)
Guaiac Fecal Occult Blood Test (gFOBT)
Stool DNA Test
Others

The FIT segment is expected to hold the largest market share due to its high sensitivity, specificity, and cost-effectiveness. The stool DNA test segment is expected to grow at the highest CAGR during the forecast period, driven by its ability to detect colorectal cancer at an early stage.

Based on end-user, the market can be segmented into:

Hospitals
Diagnostic Laboratories
Research Institutes
Others

Hospitals are expected to hold the largest market share due to the high volume of patients undergoing screening tests in hospital settings. The diagnostic laboratories segment is expected to grow at the highest CAGR during the forecast period, driven by the increasing demand for non-invasive diagnostic tests.

Based on region, the market can be segmented into:

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

North America is expected to hold the largest market share due to the high prevalence of colorectal cancer in the region and the increasing adoption of non-invasive diagnostic tests. The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, driven by the growing awareness about early detection and prevention of colorectal cancer.

Overall, the in-vitro colorectal cancer screening tests market presents significant opportunities for companies to develop new and innovative diagnostic tests and expand their global presence, driven by factors such as the increasing prevalence of colorectal cancer and the growing focus on early detection and prevention of the disease.

In-Vitro Colorectal Cancer Screening Tests Market Forecast

The in-vitro colorectal cancer screening tests market is expected to grow at a significant rate over the forecast period. According to several industry reports, the market is projected to reach USD 1.5 billion by 2028, growing at a CAGR of around 6.5% from 2021 to 2028.

This growth can be attributed to several factors, including the increasing prevalence of colorectal cancer, the growing awareness about early detection and prevention of the disease, and the rising adoption of non-invasive diagnostic tests. The fecal immunochemical test (FIT) segment is expected to dominate the market in terms of revenue due to its widespread adoption and ease of use. The stool DNA test segment is expected to grow at the highest CAGR during the forecast period, driven by its high sensitivity and specificity in detecting colorectal cancer.

North America is expected to hold the largest market share due to the high prevalence of colorectal cancer in the region and the increasing adoption of non-invasive diagnostic tests. However, the Asia-Pacific region is expected to witness the highest growth rate during the forecast period, driven by the growing awareness about early detection and prevention of colorectal cancer.

In-Vitro Colorectal Cancer Screening Tests Market Growth

The in-vitro colorectal cancer screening tests market is expected to witness significant growth in the coming years. The growth is driven by several factors, including:

Increasing prevalence of colorectal cancer: Colorectal cancer is the third most common cancer globally, with an estimated 1.9 million new cases and 935,000 deaths reported in 2020. The increasing prevalence of colorectal cancer is driving the demand for screening tests, which in turn is driving market growth.
Growing awareness about early detection and prevention: There is a growing awareness about the importance of early detection and prevention of colorectal cancer, which is driving the demand for screening tests. Many governments and healthcare organizations are promoting screening programs to detect colorectal cancer early and improve patient outcomes.
Rising adoption of non-invasive diagnostic tests: Non-invasive diagnostic tests such as FIT and stool DNA tests are gaining popularity due to their ease of use and accuracy. These tests are also less invasive and more convenient for patients, which is driving their adoption and driving market growth.
Technological advancements in screening tests: There have been significant advancements in screening test technologies, such as the development of next-generation sequencing and artificial intelligence-based tests, which are driving the demand for these tests and driving market growth.
Increasing investment in research and development: Many companies are investing in research and development to develop new and innovative screening tests. This is driving the development of new tests with improved accuracy and ease of use, which is driving market growth.

Overall, the in-vitro colorectal cancer screening tests market is expected to witness significant growth in the coming years, driven by the increasing prevalence of colorectal cancer and the growing focus on early detection and prevention of the disease.

In-Vitro Colorectal Cancer Screening Tests Market Competitor Analysis

The in-vitro colorectal cancer screening tests market is highly competitive, with several key players operating in the market. Some of the major players in the market include:

Exact Sciences Corporation: The company offers Cologuard, a non-invasive stool DNA test for the detection of colorectal cancer.
F. Hoffmann-La Roche Ltd: The company offers Cobas Epiq, a fully automated system for the detection of colorectal cancer.
Abbott Laboratories: The company offers iFOBT, a fecal occult blood test for the detection of colorectal cancer.
Sysmex Corporation: The company offers Sysmex CA-1500, an automated hematology analyzer used in the detection of colorectal cancer.
Siemens Healthineers: The company offers ADVIA Centaur XP and XPT, automated immunoassay systems used in the detection of colorectal cancer.

Other notable players in the market include Quest Diagnostics, Epigenomics AG, Eiken Chemical Co., Ltd., and Meridian Bioscience, Inc.

These companies are focusing on developing new and innovative diagnostic tests, expanding their global presence through strategic partnerships and collaborations, and investing in research and development activities. They are also focusing on improving the accuracy and sensitivity of their tests to improve patient outcomes.

The market is highly competitive, with several small and medium-sized players also operating in the market. These players are also focusing on developing new and innovative tests to gain a competitive edge in the market.

Overall, the in-vitro colorectal cancer screening tests market is highly competitive, with several key players operating in the market. Companies are focusing on developing new and innovative tests, expanding their global presence, and investing in research and development activities to gain a competitive edge in the market.

In-Vitro Colorectal Cancer Screening Tests Market Strengths

The in-vitro colorectal cancer screening tests market has several strengths that contribute to its growth and success. Some of the key strengths of the market include:

Increasing prevalence of colorectal cancer: Colorectal cancer is one of the most common cancers globally, and the increasing prevalence of the disease is driving the demand for screening tests. This presents a significant growth opportunity for companies operating in the in-vitro colorectal cancer screening tests market.
Growing awareness about early detection and prevention: There is a growing awareness about the importance of early detection and prevention of colorectal cancer. This is driving the demand for screening tests and promoting the adoption of these tests among patients and healthcare providers.
Non-invasive and convenient diagnostic tests: Non-invasive diagnostic tests, such as FIT and stool DNA tests, are gaining popularity due to their ease of use and convenience. These tests are also less invasive, making them more attractive to patients.
Technological advancements: There have been significant advancements in screening test technologies, such as the development of next-generation sequencing and artificial intelligence-based tests. These technologies offer improved accuracy and ease of use, driving the demand for screening tests.
Increasing investment in research and development: Companies are investing in research and development activities to develop new and innovative screening tests. This is driving the development of new tests with improved accuracy and ease of use, which is driving market growth.

Overall, the in-vitro colorectal cancer screening tests market has several strengths that are driving its growth and success. The increasing prevalence of colorectal cancer, growing awareness about early detection and prevention, non-invasive and convenient diagnostic tests, technological advancements, and increasing investment in research and development are all contributing to the growth of the market.

In-Vitro Colorectal Cancer Screening Tests Market Opportunities

The in-vitro colorectal cancer screening tests market presents several opportunities for growth and expansion. Some of the key opportunities in the market include:

Growing demand for non-invasive and convenient tests: There is a growing demand for non-invasive and convenient screening tests for colorectal cancer. This presents an opportunity for companies to develop new and innovative tests that are more patient-friendly and easier to use.
Increasing adoption of personalized medicine: Personalized medicine is gaining popularity, and companies can develop screening tests that are tailored to an individual’s genetic makeup. This can help improve the accuracy of the tests and provide more personalized treatment options.
Emerging markets: There is a significant growth opportunity in emerging markets such as Asia and Latin America, where the prevalence of colorectal cancer is increasing. Companies can expand their presence in these markets by developing tests that are tailored to the needs of these markets.
Technological advancements: There is an opportunity for companies to develop new and innovative technologies to improve the accuracy and ease of use of screening tests. This can help drive market growth and improve patient outcomes.
Collaboration with healthcare providers: Companies can collaborate with healthcare providers to increase awareness about the importance of colorectal cancer screening and promote the adoption of screening tests. This can help increase demand for screening tests and drive market growth.

Overall, the in-vitro colorectal cancer screening tests market presents several opportunities for growth and expansion. Companies can develop new and innovative tests that are more patient-friendly and tailored to individual needs, expand their presence in emerging markets, develop new technologies to improve test accuracy and ease of use, and collaborate with healthcare providers to increase awareness and promote the adoption of screening tests.

In-Vitro Colorectal Cancer Screening Tests Market Weakness

The in-vitro colorectal cancer screening tests market has a few weaknesses that could hinder its growth and success. Some of the key weaknesses of the market include:

Limited accuracy of some screening tests: Some screening tests, such as fecal occult blood tests, have limited accuracy and can produce false positive or false negative results. This can lead to unnecessary procedures or delayed diagnosis, which can be detrimental to patient outcomes.
High cost of some screening tests: Some screening tests can be expensive, which can limit their adoption among patients and healthcare providers. This can also lead to disparities in access to screening tests, which can be a concern.
Limited reimbursement coverage: The reimbursement coverage for some screening tests can be limited, which can limit patient access to these tests. This can also limit the adoption of new and innovative screening tests that may be more expensive than traditional tests.
Limited awareness and low adherence: Despite the growing awareness about the importance of colorectal cancer screening, there is still a lack of awareness among some patient populations. This can lead to low adherence to screening recommendations, which can be a concern.

Overall, the in-vitro colorectal cancer screening tests market has some weaknesses that could limit its growth and success. Limited accuracy of some tests, high cost, limited reimbursement coverage, and limited awareness and low adherence are all factors that could hinder the adoption of screening tests and limit market growth. However, efforts to improve test accuracy, reduce costs, increase reimbursement coverage, and improve patient awareness and adherence can help overcome these weaknesses and drive market growth.

In-Vitro Colorectal Cancer Screening Tests Market Threats

The in-vitro colorectal cancer screening tests market faces several threats that could impact its growth and sustainability. Some of the key threats to the market include:

Competition from alternative screening methods: While in-vitro screening tests are widely used, alternative screening methods such as colonoscopy and sigmoidoscopy remain popular. These methods offer more definitive results, which can limit the adoption of in-vitro tests.
Regulatory challenges: The in-vitro screening tests market is heavily regulated, and changes in regulations or new regulatory requirements can impact the development and approval of new tests. This can lead to delays in bringing new tests to market and limit market growth.
Reimbursement policies: Changes in reimbursement policies or limited reimbursement coverage can impact the adoption of screening tests. If patients are not able to afford the tests, or if healthcare providers are not reimbursed adequately, this can limit market growth.
Technological advancements: While technological advancements present an opportunity for market growth, they also pose a threat. If a company is not able to keep up with technological advancements, or if new technologies make existing tests obsolete, this can impact the market share and growth potential of companies.
Economic instability: Economic instability, such as a recession, can impact healthcare spending and limit the adoption of screening tests. This can impact market growth and sustainability.

Overall, the in-vitro colorectal cancer screening tests market faces several threats that could impact its growth and sustainability. Competition from alternative screening methods, regulatory challenges, reimbursement policies, technological advancements, and economic instability are all factors that could impact market growth. However, companies that are able to develop innovative tests that are accurate, affordable, and convenient, and that are able to navigate regulatory and reimbursement challenges, can overcome these threats and drive market growth.

Post Disclaimer

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Market Insight Lab journalist was involved in the writing and production of this article.